CereVasc Receives FDA IDE Approval to Begin Initial Clinical Study of the eShunt(R) System for Patients with Normal Pressure Hydrocephalus

BOSTON, Feb. 8, 2022 -- (Healthcare Sales & Marketing Network) -- CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today that the U.S. Food and Dr... Devices, Interventional, Neurosurgery, FDA CereVasc , eShunt System, hydrocephalus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news